Inicio
Autor Kenny Mauricio Gálvez Cárdenas
|
Comentario :
Médico Internista Hematólogo, Hospital Pablo Tobón Uribe
|
Documentos disponibles escritos por este autor (51)
Refinar búsquedaCharacteristics, outcomes and treatment patterns in acute myeloid leukemia patients 60 years or older in Colombia: a RENEHOC-PETHEMA study / Kenny Mauricio Gálvez Cárdenas ; Laura María Díaz Correa ; Sossa Melo, Claudia ; Abello Polo, Virginia ; Salazar, Luis A. ; Peña, Angela M ; González, María Luna ; Cuervo Lozada, Diana ; Quintero Vega, Guillermo E ; Daza, Jorge ; Omaña Orduz, Olga Paola ; Mantilla, William ; Perdomo, Iván ; Guerrero Burbano, Paola Andrea ; Herrera, Juan Manuel ; Idrobo, Henry ; Rodríguez Veiga, Rebeca ; Correa Correa, Mario Ernesto ; Lobatón, José ; Bermúdez, Carlos Daniel ; Pedraza Morales, Julian Eduardo ; Serrano Casas, Juan Carlos ; Jaramillo, Francisco ; Gómez, Rigoberto ; Rosales, Carmen ; Solano, María Helena ; Varón, Carlos ; Martínez Cuadrón, David ; Montesinos, Pau
Título : Characteristics, outcomes and treatment patterns in acute myeloid leukemia patients 60 years or older in Colombia: a RENEHOC-PETHEMA study Tipo de documento : documento electrónico Autores : Kenny Mauricio Gálvez Cárdenas, Autor ; Laura María Díaz Correa, Autor ; Sossa Melo, Claudia, Autor ; Abello Polo, Virginia, Autor ; Salazar, Luis A., Autor ; Peña, Angela M, Autor ; González, María Luna, Autor ; Cuervo Lozada, Diana, Autor ; Quintero Vega, Guillermo E, Autor ; Daza, Jorge, Autor ; Omaña Orduz, Olga Paola, Autor ; Mantilla, William, Autor ; Perdomo, Iván, Autor ; Guerrero Burbano, Paola Andrea, Autor ; Herrera, Juan Manuel, Autor ; Idrobo, Henry, Autor ; Rodríguez Veiga, Rebeca, Autor ; Correa Correa, Mario Ernesto, Autor ; Lobatón, José, Autor ; Bermúdez, Carlos Daniel, Autor ; Pedraza Morales, Julian Eduardo, Autor ; Serrano Casas, Juan Carlos, Autor ; Jaramillo, Francisco, Autor ; Gómez, Rigoberto, Autor ; Rosales, Carmen, Autor ; Solano, María Helena, Autor ; Varón, Carlos, Autor ; Martínez Cuadrón, David, Autor ; Montesinos, Pau, Autor Fecha de publicación : 2025 Títulos uniformes : Annals of Hematology Idioma : Inglés (eng) Palabras clave : Acute myeloid leukemia; Elderly patients; Overall survival; Treatment outcomes. Resumen : There is a limited information available on the clinical characteristics, treatment patterns and outcomes on older patients diagnosed with Acute Myeloid Leukemia (AML) in Latin-America. This multicenter retrospective study analyzed 269 patients over 60 years of age diagnosed with AML in Colombia, using data from RENEHOC-PETHEMA registry, from 2009 to 2023. The median age at diagnosis was 70 years (Range:60-98), 55% were men, 61% had an ECOG Mención de responsabilidad : Claudia Sossa-Melo, Virginia Abello-Polo, Luis A Salazar, Angela M Peña, María Luna-González 4, Diana Cuervo-Lozada, Guillermo E Quintero-Vega, Jorge Daza, Olga Paola Omaña-Orduz, William Mantilla, Iván Perdomo, Kenny Galvez, Laura María Díaz-Correa, Paola Andrea Guerrero-Burbano, Juan Manuel Herrera, Henry Idrobo, L M Gaviria, Mario Ernesto Correa-Correa, José Lobatón, Carlos Daniel Bermúdez, Julian Eduardo Pedraza-Morales, Juan Carlos Serrano-Casas, Francisco Jaramillo, Rigoberto Gómez, Carmen Rosales, María Helena Solano, Carlos Varón, Rebeca Rodríguez-Veiga, David Martínez-Cuadrón, Pau Montesinos. Referencia : Ann Hematol . 2025 Jan;104(1):369-381 DOI (Digital Object Identifier) : 10.1007/s00277-024-06120-0 PMID : 39815122 Derechos de uso : CC BY-NC-ND En línea : https://pubmed-ncbi-nlm-nih-gov.consultaremota.upb.edu.co/39815122/ Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_dis Characteristics, outcomes and treatment patterns in acute myeloid leukemia patients 60 years or older in Colombia: a RENEHOC-PETHEMA study [documento electrónico] / Kenny Mauricio Gálvez Cárdenas, Autor ; Laura María Díaz Correa, Autor ; Sossa Melo, Claudia, Autor ; Abello Polo, Virginia, Autor ; Salazar, Luis A., Autor ; Peña, Angela M, Autor ; González, María Luna, Autor ; Cuervo Lozada, Diana, Autor ; Quintero Vega, Guillermo E, Autor ; Daza, Jorge, Autor ; Omaña Orduz, Olga Paola, Autor ; Mantilla, William, Autor ; Perdomo, Iván, Autor ; Guerrero Burbano, Paola Andrea, Autor ; Herrera, Juan Manuel, Autor ; Idrobo, Henry, Autor ; Rodríguez Veiga, Rebeca, Autor ; Correa Correa, Mario Ernesto, Autor ; Lobatón, José, Autor ; Bermúdez, Carlos Daniel, Autor ; Pedraza Morales, Julian Eduardo, Autor ; Serrano Casas, Juan Carlos, Autor ; Jaramillo, Francisco, Autor ; Gómez, Rigoberto, Autor ; Rosales, Carmen, Autor ; Solano, María Helena, Autor ; Varón, Carlos, Autor ; Martínez Cuadrón, David, Autor ; Montesinos, Pau, Autor . - 2025.
Obra : Annals of Hematology
Idioma : Inglés (eng)
Palabras clave : Acute myeloid leukemia; Elderly patients; Overall survival; Treatment outcomes. Resumen : There is a limited information available on the clinical characteristics, treatment patterns and outcomes on older patients diagnosed with Acute Myeloid Leukemia (AML) in Latin-America. This multicenter retrospective study analyzed 269 patients over 60 years of age diagnosed with AML in Colombia, using data from RENEHOC-PETHEMA registry, from 2009 to 2023. The median age at diagnosis was 70 years (Range:60-98), 55% were men, 61% had an ECOG Mención de responsabilidad : Claudia Sossa-Melo, Virginia Abello-Polo, Luis A Salazar, Angela M Peña, María Luna-González 4, Diana Cuervo-Lozada, Guillermo E Quintero-Vega, Jorge Daza, Olga Paola Omaña-Orduz, William Mantilla, Iván Perdomo, Kenny Galvez, Laura María Díaz-Correa, Paola Andrea Guerrero-Burbano, Juan Manuel Herrera, Henry Idrobo, L M Gaviria, Mario Ernesto Correa-Correa, José Lobatón, Carlos Daniel Bermúdez, Julian Eduardo Pedraza-Morales, Juan Carlos Serrano-Casas, Francisco Jaramillo, Rigoberto Gómez, Carmen Rosales, María Helena Solano, Carlos Varón, Rebeca Rodríguez-Veiga, David Martínez-Cuadrón, Pau Montesinos. Referencia : Ann Hematol . 2025 Jan;104(1):369-381 DOI (Digital Object Identifier) : 10.1007/s00277-024-06120-0 PMID : 39815122 Derechos de uso : CC BY-NC-ND En línea : https://pubmed-ncbi-nlm-nih-gov.consultaremota.upb.edu.co/39815122/ Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_dis Reserva
Reservar este documento
Ejemplares(1)
Código de barras Número de Ubicación Tipo de medio Ubicación Sección Estado DD002333 AC-2025-016 Archivo digital Producción Científica Artículos científicos Disponible
Título : Experience in the diagnosis and treatment of AL amyloidosis in a high-complexity center in Medellín, Colombia Tipo de documento : documento electrónico Autores : Kenny Mauricio Gálvez Cárdenas, Autor ; Morantes Rubiano, Juan Felipe, Autor ; Cardenas, Valentina, Autor Fecha de publicación : 2025 Títulos uniformes : blood glo Idioma : Inglés (eng) Palabras clave : In patients with multiple myeloma it is necessary to have high clinical suspicion to rule out the presence of AL amyloidosis. Resumen : This study describes the demographic, clinical, paraclinical, imaging, therapeutic, and prognostic characteristics in patients with immunoglobulin light chain (AL) amyloidosis in a high-complexity institution. A retrospective cohort of patients diagnosed with AL amyloidosis was assessed at the Pablo Tobón Uribe Hospital in Medellín, Colombia, from January 2010 to May 2023. A total of 33 patients were included, of whom 20 (60.6%) were women, and the median age was 62 (range, 48-77) years. According to the revised Mayo Clinic staging system, disease stratification was 29.6%, 44.4%, 11.1%, and 7% for stages I, II, III, and IV, respectively. Multiple myeloma and Waldenström’s macroglobulinemia were present in 22 (66%) and 1 (3%) patient, respectively. The median overall survival was 66 months (interquartile range [IQR], 30-119), which decreased to 35 months (IQR, 10-63) with cardiac involvement and to 33 months (IQR, 11-55) with concurrent multiple myeloma. In contrast, patients who underwent hematopoietic transplantation had a longer survival of 136 months (IQR, 33-136). The 5-year overall survival was 44.9% (95% confidence interval, 26.8-63). Our findings are consistent with the existing literature, with some distinctions such as a female predominance and high frequency of concurrent multiple myeloma. Cardiac involvement, multiple myeloma, and renal involvement were associated with reduced overall survival, suggesting their role as adverse prognostic factors. Mención de responsabilidad : Kenny Galvez, Juan Felipe Morantes Rubiano, Valentina Cardenas DOI (Digital Object Identifier) : 10.1016/j.bglo.2025.100015 Derechos de uso : CC BY-NC-ND En línea : https://www.sciencedirect.com/science/article/pii/S3050565825000150 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_dis Experience in the diagnosis and treatment of AL amyloidosis in a high-complexity center in Medellín, Colombia [documento electrónico] / Kenny Mauricio Gálvez Cárdenas, Autor ; Morantes Rubiano, Juan Felipe, Autor ; Cardenas, Valentina, Autor . - 2025.
Obra : blood glo
Idioma : Inglés (eng)
Palabras clave : In patients with multiple myeloma it is necessary to have high clinical suspicion to rule out the presence of AL amyloidosis. Resumen : This study describes the demographic, clinical, paraclinical, imaging, therapeutic, and prognostic characteristics in patients with immunoglobulin light chain (AL) amyloidosis in a high-complexity institution. A retrospective cohort of patients diagnosed with AL amyloidosis was assessed at the Pablo Tobón Uribe Hospital in Medellín, Colombia, from January 2010 to May 2023. A total of 33 patients were included, of whom 20 (60.6%) were women, and the median age was 62 (range, 48-77) years. According to the revised Mayo Clinic staging system, disease stratification was 29.6%, 44.4%, 11.1%, and 7% for stages I, II, III, and IV, respectively. Multiple myeloma and Waldenström’s macroglobulinemia were present in 22 (66%) and 1 (3%) patient, respectively. The median overall survival was 66 months (interquartile range [IQR], 30-119), which decreased to 35 months (IQR, 10-63) with cardiac involvement and to 33 months (IQR, 11-55) with concurrent multiple myeloma. In contrast, patients who underwent hematopoietic transplantation had a longer survival of 136 months (IQR, 33-136). The 5-year overall survival was 44.9% (95% confidence interval, 26.8-63). Our findings are consistent with the existing literature, with some distinctions such as a female predominance and high frequency of concurrent multiple myeloma. Cardiac involvement, multiple myeloma, and renal involvement were associated with reduced overall survival, suggesting their role as adverse prognostic factors. Mención de responsabilidad : Kenny Galvez, Juan Felipe Morantes Rubiano, Valentina Cardenas DOI (Digital Object Identifier) : 10.1016/j.bglo.2025.100015 Derechos de uso : CC BY-NC-ND En línea : https://www.sciencedirect.com/science/article/pii/S3050565825000150 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_dis Reserva
Reservar este documento
Ejemplares(1)
Código de barras Número de Ubicación Tipo de medio Ubicación Sección Estado DD002384 AC-2025-067 Archivo digital Producción Científica Artículos científicos Disponible
Título : Healthcare Systems as Determinants of Outcomes in Multiple Myeloma: Final Results from the Latin American MYLACRE Study Tipo de documento : documento electrónico Autores : Kenny Mauricio Gálvez Cárdenas, Autor ; Hungria, Vania, Autor ; Gaiolla, Rafael, Autor ; Remaggi, Guillermina, Autor ; Schutz, Natalia, Autor ; Bittencourt, Rosane, Autor ; Maiolino, Angelo, Autor ; Quintero Vega, Guillermo E, Autor ; Silvana Cugliari, Maria, Autor ; Tobias Braga, Walter Moises, Autor ; Colaco Villarim, Carolina, Autor ; Crusoe, Edvan, Autor ; Enrico, Alicia Ines, Autor ; Caiero, Gaston, Autor ; Bigonha, Jandey, Autor ; Lemos Moura, Fernanda, Autor ; Figueroa, Jair, Autor ; Sossa Melo, Claudia Lucia, Autor ; Lombana, Milton, Autor ; Pei, Huiling, Autor ; Fernandez, Mariana, Autor ; Saes, Jaqueline, Autor ; Trufelli, Damila Cristina, Autor Fecha de publicación : 2025 Títulos uniformes : Blood Advances Idioma : Inglés (eng) Resumen : Although systemic therapy for multiple myeloma (MM) has evolved considerably over the past 2 decades, state-of-the-art treatment is not uniformly available in Latin America. In some countries, disparities between the public and private sectors in clinical presentation, access to novel agents, and transplantation are striking, with the public sector lagging. We conducted a multicenter, observational study of patients with MM in 5 Latin American countries (Argentina, Brazil, Colombia, Mexico, and Panama). We enrolled patients aged ?18 years diagnosed with MM between January 2016 and June 2021, using data collected between May 2019 and June 2022. We categorized institutions as “public” when primarily funded by federal or local government, and “private” when financed mostly or completely by other sources. We analyzed 1029 patients, 1021 of whom could be classified into public (n = 339) and private (n = 682) institutions. These 2 groups differed in many respects, with patients from the latter having better baseline prognostic features (including eligibility to transplantation) and receiving combinations of immunomodulatory drugs and proteasome inhibitors, as well as anti-CD38 antibodies, more frequently than patients from public institutions. Among 960 patients with complete data for this analysis, the median overall survival was 44.6 months in public institutions and 53.3 months in private institutions (hazard ratio, 0.84; 95% confidence interval, 0.67-1.04; P = .109). Our results indicate diagnostic and therapeutic shortcomings in the management of MM in Latin America, with important gaps in patient profile, treatment patterns and long-term outcomes between public and private institutions. Mención de responsabilidad : Vania Hungria, Rafael Gaiolla, Kenny Galvez, Guillermina Remaggi, Natalia Schutz, Rosane Bittencourt, Angelo Maiolino, Guillermo Quintero, Maria Silvana Cugliari, Walter Moises Tobias Braga, Carolina Colaco Villarim, Edvan Crusoe, Alicia Ines Enrico, Gaston Caiero, Jandey Bigonha, Fernanda Lemos Moura, Jair Figueroa, Claudia Lucia Sossa Melo, Milton Lombana, Huiling Pei, Mariana Fernandez, Jaqueline Saes, Damila Cristina Trufelli. Referencia : Blood Advances Volume 9, Issue 6, 25 March 2025, Pages 1293-1302 DOI (Digital Object Identifier) : 10.1182/bloodadvances.2024013838 Derechos de uso : CC BY-NC-ND En línea : https://www.sciencedirect.com/science/article/pii/S2473952924007146 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_dis Healthcare Systems as Determinants of Outcomes in Multiple Myeloma: Final Results from the Latin American MYLACRE Study [documento electrónico] / Kenny Mauricio Gálvez Cárdenas, Autor ; Hungria, Vania, Autor ; Gaiolla, Rafael, Autor ; Remaggi, Guillermina, Autor ; Schutz, Natalia, Autor ; Bittencourt, Rosane, Autor ; Maiolino, Angelo, Autor ; Quintero Vega, Guillermo E, Autor ; Silvana Cugliari, Maria, Autor ; Tobias Braga, Walter Moises, Autor ; Colaco Villarim, Carolina, Autor ; Crusoe, Edvan, Autor ; Enrico, Alicia Ines, Autor ; Caiero, Gaston, Autor ; Bigonha, Jandey, Autor ; Lemos Moura, Fernanda, Autor ; Figueroa, Jair, Autor ; Sossa Melo, Claudia Lucia, Autor ; Lombana, Milton, Autor ; Pei, Huiling, Autor ; Fernandez, Mariana, Autor ; Saes, Jaqueline, Autor ; Trufelli, Damila Cristina, Autor . - 2025.
Obra : Blood Advances
Idioma : Inglés (eng)
Resumen : Although systemic therapy for multiple myeloma (MM) has evolved considerably over the past 2 decades, state-of-the-art treatment is not uniformly available in Latin America. In some countries, disparities between the public and private sectors in clinical presentation, access to novel agents, and transplantation are striking, with the public sector lagging. We conducted a multicenter, observational study of patients with MM in 5 Latin American countries (Argentina, Brazil, Colombia, Mexico, and Panama). We enrolled patients aged ?18 years diagnosed with MM between January 2016 and June 2021, using data collected between May 2019 and June 2022. We categorized institutions as “public” when primarily funded by federal or local government, and “private” when financed mostly or completely by other sources. We analyzed 1029 patients, 1021 of whom could be classified into public (n = 339) and private (n = 682) institutions. These 2 groups differed in many respects, with patients from the latter having better baseline prognostic features (including eligibility to transplantation) and receiving combinations of immunomodulatory drugs and proteasome inhibitors, as well as anti-CD38 antibodies, more frequently than patients from public institutions. Among 960 patients with complete data for this analysis, the median overall survival was 44.6 months in public institutions and 53.3 months in private institutions (hazard ratio, 0.84; 95% confidence interval, 0.67-1.04; P = .109). Our results indicate diagnostic and therapeutic shortcomings in the management of MM in Latin America, with important gaps in patient profile, treatment patterns and long-term outcomes between public and private institutions. Mención de responsabilidad : Vania Hungria, Rafael Gaiolla, Kenny Galvez, Guillermina Remaggi, Natalia Schutz, Rosane Bittencourt, Angelo Maiolino, Guillermo Quintero, Maria Silvana Cugliari, Walter Moises Tobias Braga, Carolina Colaco Villarim, Edvan Crusoe, Alicia Ines Enrico, Gaston Caiero, Jandey Bigonha, Fernanda Lemos Moura, Jair Figueroa, Claudia Lucia Sossa Melo, Milton Lombana, Huiling Pei, Mariana Fernandez, Jaqueline Saes, Damila Cristina Trufelli. Referencia : Blood Advances Volume 9, Issue 6, 25 March 2025, Pages 1293-1302 DOI (Digital Object Identifier) : 10.1182/bloodadvances.2024013838 Derechos de uso : CC BY-NC-ND En línea : https://www.sciencedirect.com/science/article/pii/S2473952924007146 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_dis Reserva
Reservar este documento
Ejemplares(1)
Código de barras Número de Ubicación Tipo de medio Ubicación Sección Estado DD002345 AC-2025-028 Archivo digital Producción Científica Artículos científicos Disponible
Título : Prognostic value of PET/CT in newly diagnosed multiple myeloma: A Bayesian analysis with missing data imputation Tipo de documento : documento electrónico Autores : Kenny Mauricio Gálvez Cárdenas, Autor ; González Artunduaga, Eliana Andrea, Autor ; Cruz Gutiérrez, Nelson Alirio, Autor ; Sandoval Álvarez, Simón, Autor Fecha de publicación : 2025 Títulos uniformes : Cancer Research Idioma : Inglés (eng) Resumen : Introduction PET/CT assessment in newly diagnosed patients with multiple myeloma is a significant predictor of long-term clinical outcomes. Incorporating this imaging technique into a Bayesian analysis that addresses data gaps allows for more accurate prognostic estimates. This methodology enhances our understanding of the disease and guides informed clinical decisions, ultimately improving patient care. Objective This study aims to evaluate the prognostic value of PET/CT in newly diagnosed patients with multiple myeloma, using Bayesian analysis to manage missing data imputation. We seek to determine how PET/CT findings predict long-term clinical outcomes, thereby enhancing treatment personalization. Hypotheses: A positive PET/CT at diagnosis may correlate with poor prognosis, indicating lower survival rates and worse disease control. A negative PET/CT at diagnosis may be associated with better prognosis, suggesting higher treatment response rates and longer survival. Study Design An analytical study based on clinical and imaging data from PET/CT. Study Population Patients diagnosed with multiple myeloma between 2017 and 2024 at an institution in Medellín, Colombia, approved by the ethics committee of Pablo Tobón Hospital. Variables of Interest: Clinical Variables: Age, sex, type of treatment. PET/CT Variables: Positive (+), negative (-). Other Variables: Cytogenetics, Beta 2 Microglobulin (B2M), Bone Marrow Biopsy, Albumin, Hemoglobin. Outcome Variables: Overall Survival, Progression-Free Survival, Treatment Response. Data Imputation Methodology Using advanced R tools, including: MCMC: For parameter estimation despite incomplete data. SMC: To optimize sequential inferences and improve precision. Statistical Analysis: Kaplan-Meier survival curves for visualizing survival rates. Significance of covariates evaluated through 95% credibility intervals. Results The Bayesian model highlights PET/CT and cytogenetics as key outcome variables. A negative PET/CT correlates with better survival and more accurate treatment response prediction, while a positive PET/CT is linked to higher disease progression rates. Limitations Generalizability may be limited due to single-institution data. Missing data could introduce bias despite imputation methods. Short follow-up may restrict long-term outcome assessment. Variability in imaging protocols may affect result consistency. Conclusions Prognostic Value of PET/CT: The study indicates that PET/CT evaluation is a significant predictor of long-term outcomes in multiple myeloma. A negative PET/CT is linked to better prognosis and treatment response. Clinical Decision Making: Integrating Bayesian analysis and data imputation into PET/CT assessment enhances prognostic accuracy, providing clinicians with valuable insights for personalized treatment and optimized patient care. Citation Format Eliana Andrea González Artunduaga, Nelson Alirio Cruz Gutiérrez, Simón Sandoval Álvarez, Kenny Mauricio Gálvez Cárdenas. Prognostic value of PET/CT in newly diagnosed multiple myeloma: A Bayesian analysis with missing data imputation [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 1 (Regular Abstracts); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_1):Abstract nr 4516. Mención de responsabilidad : Eliana Andrea González Artunduaga; Nelson Alirio Cruz Gutiérrez; Simón Sandoval Álvarez; Kenny Mauricio Gálvez Cárdenas Referencia : Cancer Res (2025) 85 (8_Supplement_1): 4516. DOI (Digital Object Identifier) : 10.1158/1538-7445.AM2025-4516 Derechos de uso : CC BY-NC-ND En línea : https://aacrjournals.org/cancerres/article/85/8_Supplement_1/4516/757005 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_dis Prognostic value of PET/CT in newly diagnosed multiple myeloma: A Bayesian analysis with missing data imputation [documento electrónico] / Kenny Mauricio Gálvez Cárdenas, Autor ; González Artunduaga, Eliana Andrea, Autor ; Cruz Gutiérrez, Nelson Alirio, Autor ; Sandoval Álvarez, Simón, Autor . - 2025.
Obra : Cancer Research
Idioma : Inglés (eng)
Resumen : Introduction PET/CT assessment in newly diagnosed patients with multiple myeloma is a significant predictor of long-term clinical outcomes. Incorporating this imaging technique into a Bayesian analysis that addresses data gaps allows for more accurate prognostic estimates. This methodology enhances our understanding of the disease and guides informed clinical decisions, ultimately improving patient care. Objective This study aims to evaluate the prognostic value of PET/CT in newly diagnosed patients with multiple myeloma, using Bayesian analysis to manage missing data imputation. We seek to determine how PET/CT findings predict long-term clinical outcomes, thereby enhancing treatment personalization. Hypotheses: A positive PET/CT at diagnosis may correlate with poor prognosis, indicating lower survival rates and worse disease control. A negative PET/CT at diagnosis may be associated with better prognosis, suggesting higher treatment response rates and longer survival. Study Design An analytical study based on clinical and imaging data from PET/CT. Study Population Patients diagnosed with multiple myeloma between 2017 and 2024 at an institution in Medellín, Colombia, approved by the ethics committee of Pablo Tobón Hospital. Variables of Interest: Clinical Variables: Age, sex, type of treatment. PET/CT Variables: Positive (+), negative (-). Other Variables: Cytogenetics, Beta 2 Microglobulin (B2M), Bone Marrow Biopsy, Albumin, Hemoglobin. Outcome Variables: Overall Survival, Progression-Free Survival, Treatment Response. Data Imputation Methodology Using advanced R tools, including: MCMC: For parameter estimation despite incomplete data. SMC: To optimize sequential inferences and improve precision. Statistical Analysis: Kaplan-Meier survival curves for visualizing survival rates. Significance of covariates evaluated through 95% credibility intervals. Results The Bayesian model highlights PET/CT and cytogenetics as key outcome variables. A negative PET/CT correlates with better survival and more accurate treatment response prediction, while a positive PET/CT is linked to higher disease progression rates. Limitations Generalizability may be limited due to single-institution data. Missing data could introduce bias despite imputation methods. Short follow-up may restrict long-term outcome assessment. Variability in imaging protocols may affect result consistency. Conclusions Prognostic Value of PET/CT: The study indicates that PET/CT evaluation is a significant predictor of long-term outcomes in multiple myeloma. A negative PET/CT is linked to better prognosis and treatment response. Clinical Decision Making: Integrating Bayesian analysis and data imputation into PET/CT assessment enhances prognostic accuracy, providing clinicians with valuable insights for personalized treatment and optimized patient care. Citation Format Eliana Andrea González Artunduaga, Nelson Alirio Cruz Gutiérrez, Simón Sandoval Álvarez, Kenny Mauricio Gálvez Cárdenas. Prognostic value of PET/CT in newly diagnosed multiple myeloma: A Bayesian analysis with missing data imputation [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 1 (Regular Abstracts); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_1):Abstract nr 4516. Mención de responsabilidad : Eliana Andrea González Artunduaga; Nelson Alirio Cruz Gutiérrez; Simón Sandoval Álvarez; Kenny Mauricio Gálvez Cárdenas Referencia : Cancer Res (2025) 85 (8_Supplement_1): 4516. DOI (Digital Object Identifier) : 10.1158/1538-7445.AM2025-4516 Derechos de uso : CC BY-NC-ND En línea : https://aacrjournals.org/cancerres/article/85/8_Supplement_1/4516/757005 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_dis Reserva
Reservar este documento
Ejemplares(1)
Código de barras Número de Ubicación Tipo de medio Ubicación Sección Estado DD002390 AC-2025-073 Archivo digital Producción Científica Artículos científicos Disponible
Título : Real World Evidence From 2 Decades of First-Line TKI Therapy in Chronic Myeloid Leukemia (CML): Insights From ACHO's RENEHOC Registry Tipo de documento : documento electrónico Autores : Kenny Mauricio Gálvez Cárdenas, Autor ; Munevar, Isabel, Autor ; Idrobo, Henry, Autor ; Armando Mantilla, William, Autor ; Domingo Saavedra Ramírez, Autor Fecha de publicación : 2025 Títulos uniformes : Clinical Lymphoma, Myeloma and Leukemia Idioma : Inglés (eng) Palabras clave : Dasatinib; Imatinib; Nilotinib; RENEHOC registry; Tyrosine kinase inhibitors Resumen : Background: Chronic myeloid leukemia (CML) treatment has significantly evolved with the introduction of tyrosine kinase inhibitors. However, access to these treatments and outcomes vary globally. This study examines 2 decades of CML management in Colombia using the RENEHOC registry, focusing on TKI efficacy, safety, and healthcare system challenges. Methods: We performed a descriptive analysis of the sociodemographic and clinical characteristics of 994 CML patients from the RENEHOC cohort in Colombia, who were treated over the past 20 years. Trends in first-line TKI use were assessed, and Kaplan-Meier survival curves were used to estimate EFS and OS. The log-rank test was used to compare survival curves between different first-line TKIs. Results: The analysis shows trends in the use of first-line TKIs over a 20-year period in Colombia, where, as in other countries, the use of second-generation TKIs in the first-line setting is gradually increasing. Despite the difficulties of the Colombian healthcare system, the results in terms of OS are excellent regardless of the first-line TKI; however, patients treated with imatinib switched lines significantly more often than those treated with second-generation TKIs (imatinib 58.7%, nilotinib 19.5%, dasatinib 29.3%). The median duration of treatment was significantly shorter with imatinib compared to dasatinib and nilotinib (4.08, 12.75 and not reached, respectively). Intolerance was the most common reason for switching in this cohort of patients. The median observation time for OS was 64.89 months (SD 60.15), with survival rates of 99.4% at 1 year, 97.7% at 3 years and 96.6% at 5 years. Conclusions: The results of this analysis show excellent results in terms of OS for patients with CML treated in Colombia over the last 20 years, despite the difficulties inherent in the health system. Patients treated with first-line imatinib had more frequent line changes. In general, intolerance was the most common reason for switching lines. Despite its retrospective nature, this study allows us to outline how treatment patterns in the country have changed over time. Continued efforts to include more centers and patients in prospective studies are essential to better understand the long-term effects of treatment and to improve adherence to guideline recommendations in clinical practice. © 2024 The Authors Mención de responsabilidad : Abello Polo, Virginia, Sossa, Claudia, Boquimpani, Carla, Salazar, Luis Antonio, Munevar, Isabel, Gómez, Rigoberto, Cuervo, Diana Marcela, Varón Jaimes, Carlos, Reyes, Jheremy, Idrobo, Henry, Omaña, Paola, Daza, Jorge, Pedraza Morales, Julian Eduardo, Agudelo López, Claudia, Quintero-Vega, Guillermo E., Correa Correa, Mario, Herrera, Juan Manuel, Mantilla, William Armando, Serrano, Juan Carlos, Rosales, Carmen, Gálvez Cárdenas, Kenny Mauricio, Bermúdez, Carlos, Saavedra Ramírez, Domingo, Alzate, Mauricio, Lobatón Ramírez, José Fernando Referencia : Clin Lymphoma Myeloma Leuk . 2024 Dec 28:S2152-2650(24)02464-9. DOI (Digital Object Identifier) : 10.1016/j.clml.2024.12.015 PMID : 39863461 Derechos de uso : CC BY-NC-ND En línea : https://pubmed.ncbi.nlm.nih.gov/39863461/ Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_dis Real World Evidence From 2 Decades of First-Line TKI Therapy in Chronic Myeloid Leukemia (CML): Insights From ACHO's RENEHOC Registry [documento electrónico] / Kenny Mauricio Gálvez Cárdenas, Autor ; Munevar, Isabel, Autor ; Idrobo, Henry, Autor ; Armando Mantilla, William, Autor ; Domingo Saavedra Ramírez, Autor . - 2025.
Obra : Clinical Lymphoma, Myeloma and Leukemia
Idioma : Inglés (eng)
Palabras clave : Dasatinib; Imatinib; Nilotinib; RENEHOC registry; Tyrosine kinase inhibitors Resumen : Background: Chronic myeloid leukemia (CML) treatment has significantly evolved with the introduction of tyrosine kinase inhibitors. However, access to these treatments and outcomes vary globally. This study examines 2 decades of CML management in Colombia using the RENEHOC registry, focusing on TKI efficacy, safety, and healthcare system challenges. Methods: We performed a descriptive analysis of the sociodemographic and clinical characteristics of 994 CML patients from the RENEHOC cohort in Colombia, who were treated over the past 20 years. Trends in first-line TKI use were assessed, and Kaplan-Meier survival curves were used to estimate EFS and OS. The log-rank test was used to compare survival curves between different first-line TKIs. Results: The analysis shows trends in the use of first-line TKIs over a 20-year period in Colombia, where, as in other countries, the use of second-generation TKIs in the first-line setting is gradually increasing. Despite the difficulties of the Colombian healthcare system, the results in terms of OS are excellent regardless of the first-line TKI; however, patients treated with imatinib switched lines significantly more often than those treated with second-generation TKIs (imatinib 58.7%, nilotinib 19.5%, dasatinib 29.3%). The median duration of treatment was significantly shorter with imatinib compared to dasatinib and nilotinib (4.08, 12.75 and not reached, respectively). Intolerance was the most common reason for switching in this cohort of patients. The median observation time for OS was 64.89 months (SD 60.15), with survival rates of 99.4% at 1 year, 97.7% at 3 years and 96.6% at 5 years. Conclusions: The results of this analysis show excellent results in terms of OS for patients with CML treated in Colombia over the last 20 years, despite the difficulties inherent in the health system. Patients treated with first-line imatinib had more frequent line changes. In general, intolerance was the most common reason for switching lines. Despite its retrospective nature, this study allows us to outline how treatment patterns in the country have changed over time. Continued efforts to include more centers and patients in prospective studies are essential to better understand the long-term effects of treatment and to improve adherence to guideline recommendations in clinical practice. © 2024 The Authors Mención de responsabilidad : Abello Polo, Virginia, Sossa, Claudia, Boquimpani, Carla, Salazar, Luis Antonio, Munevar, Isabel, Gómez, Rigoberto, Cuervo, Diana Marcela, Varón Jaimes, Carlos, Reyes, Jheremy, Idrobo, Henry, Omaña, Paola, Daza, Jorge, Pedraza Morales, Julian Eduardo, Agudelo López, Claudia, Quintero-Vega, Guillermo E., Correa Correa, Mario, Herrera, Juan Manuel, Mantilla, William Armando, Serrano, Juan Carlos, Rosales, Carmen, Gálvez Cárdenas, Kenny Mauricio, Bermúdez, Carlos, Saavedra Ramírez, Domingo, Alzate, Mauricio, Lobatón Ramírez, José Fernando Referencia : Clin Lymphoma Myeloma Leuk . 2024 Dec 28:S2152-2650(24)02464-9. DOI (Digital Object Identifier) : 10.1016/j.clml.2024.12.015 PMID : 39863461 Derechos de uso : CC BY-NC-ND En línea : https://pubmed.ncbi.nlm.nih.gov/39863461/ Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_dis Reserva
Reservar este documento
Ejemplares(1)
Código de barras Número de Ubicación Tipo de medio Ubicación Sección Estado DD002322 AC-2025-005 Archivo digital Producción Científica Artículos científicos Disponible 
Permalink
Permalink
Permalink
Permalink
Permalink
Permalink
Permalink
Permalink
Permalink
Permalink
